ArticleGenome medicine2014
Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia.
Article in Genome medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- DNMT3A-R882 mutation promotes acute myeloid leukemia progression by recruiting E2H2 to inhibit circKCNQ5 methylation.Discover oncology · 2025Article
- Article
- Review
- Relationship of ITPKA expression with the prognosis of breast cancer.Molecular genetics & genomic medicine · 2021Article
- Frizzled Receptors in Tumors, Focusing on Signaling, Roles, Modulation Mechanisms, and Targeted Therapies.Oncology research · 2021Review
- Cancer chemoprevention through Frizzled receptors and EMT.Discover oncology · 2021Review
- Identification of Methylation-Regulated Differentially Expressed Genes and Related Pathways in Hepatocellular Carcinoma: A Study Based on TCGA Database and Bioinformatics Analysis.Frontiers in oncology · 2021Article
- The multifarious roles of the chemokine CXCL14 in cancer progression and immune responses.Molecular carcinogenesis · 2020Review
- Systematic Construction and Validation of a Metabolic Risk Model for Prognostic Prediction in Acute Myelogenous Leukemia.Frontiers in oncology · 2020Article
- Comprehensive analysis of histone modification-associated genes on differential gene expression and prognosis in gastric cancer.Experimental and therapeutic medicine · 2019Article
- The transcriptomic and epigenetic map of vascular quiescence in the continuous lung endothelium.eLife · 2018Article
- Mining the glioma susceptibility genes in children from gene expression profiles and a methylation database.Oncology letters · 2017Article
- High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions.Journal of translational medicine · 2017Article
- Fatty acid-binding protein FABP4 mechanistically links obesity with aggressive AML by enhancing aberrant DNA methylation in AML cells.Leukemia · 2017Article
- The Regulatory Capacity of Bivalent Genes-A Theoretical Approach.International journal of molecular sciences · 2017Article
- Article
- The epigenetic regulation of CXCL14 plays a role in the pathobiology of oral cancers.Journal of Cancer · 2017Article
- Expression of the chemokine CXCL14 and cetuximab-dependent tumour suppression in head and neck squamous cell carcinoma.Oncogenesis · 2016Article
- Epigenetics: A primer for clinicians.Blood reviews · 2016Review
- Hypermethylated in cancer 1(HIC1) suppresses non-small cell lung cancer progression by targeting interleukin-6/Stat3 pathway.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAberrant DNA methylation is frequently found in human malignancies including acute myeloid leukemia (AML). While most studies focus on later disease stages, the onset of aberrant DNA methylation events and their dynamics during leukemic progression are largely unknown.
methodsWe screened genome-wide for aberrant CpG island methylation in three disease stages of a murine AML model that is driven by hypomorphic expression of the hematopoietic transcription factor PU.1. DNA methylation levels of selected genes were correlated with methylation levels of CD34+ cells and lineage negative, CD127-, c-Kit+, Sca-1+ cells; common myeloid progenitors; granulocyte-macrophage progenitors; and megakaryocyte-erythroid progenitors.
resultsWe identified 1,184 hypermethylated array probes covering 762 associated genes in the preleukemic stage. During disease progression, the number of hypermethylated genes increased to 5,465 in the late leukemic disease stage. Using publicly available data, we found a significant enrichment of PU.1 binding sites in the preleukemic hypermethylated genes, suggesting that shortage of PU.1 makes PU.1 binding sites in the DNA accessible for aberrant methylation. Many known AML associated genes such as RUNX1 and HIC1 were found among the preleukemic hypermethylated genes. Nine novel hypermethylated genes, FZD5, FZD8, PRDM16, ROBO3, CXCL14, BCOR, ITPKA, HES6 and TAL1, the latter four being potential PU.1 targets, were confirmed to be hypermethylated in human normal karyotype AML patients, underscoring the relevance of the mouse model for human AML.
conclusionsOur study identified early aberrantly methylated genes as potential contributors to onset and progression of AML.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.